Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Monday, December 23, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
RTX’s Collins Aerospace announces avionics modernization program for King Air and…
Aptar and Nadara Collaborate to Drive Renewable Energy Generation in Europe
KalVista Appoints Jeb Ledell as Chief Operating Officer
Biocytogen Announces Adcendo ApS Exercises Antibody Option
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
AMTX-100 CF3
AMTX-100 CF3
Biotechnology
Amytrx Therapeutic’s AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
PR Newswire
-
June 13, 2022
Amytrx and Amarex Clinical Research, LLC, an NSF company, announced they are initiating the Phase II clinical trial on atopic dermatitis (AD) using Amytrx's...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
RTX’s Collins Aerospace announces avionics modernization program for King Air and Hawker aircraft
Aptar and Nadara Collaborate to Drive Renewable Energy Generation in Europe
KalVista Appoints Jeb Ledell as Chief Operating Officer
Load more
